EE41 Cost Effectiveness of Romosozumab Followed by Alendronate Versus Teriparatide in the Treatment of Severe Osteoporosis in Greece

Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.314
https://www.valueinhealthjournal.com/article/S1098-3015(23)03444-7/fulltext
Title : EE41 Cost Effectiveness of Romosozumab Followed by Alendronate Versus Teriparatide in the Treatment of Severe Osteoporosis in Greece
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03444-7&doi=10.1016/j.jval.2023.09.314
First page :
Section Title :
Open access? : No
Section Order : 12336
Categories :
Tags :
Regions :
ViH Article Tags :